16 September 2026 editorial review · Item
Insulin aspart (NovoLog / NovoRapid): review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the item evidence page →Thriving evidence review — 16 September 2026
Record: Insulin aspart (NovoLog / NovoRapid)
Scope and findings:
- US label confirms rapid analogue,1–3h glucose-effect peak,3–5h duration,40–50min serum peak,81min apparent half-life and pump-specific instructions. Removed blanket halve-dose exercise advice. Biosimilar/price/Cochrane claims need separate source review.
Primary sources checked:
Limits: The review is restricted to the scopes above. Historical efficacy estimates, editorial scoring and country-specific access were not fully reverified unless expressly stated. A manufacturer or conference report retains that evidence level.